Access cutting-edge primary hyperoxaluria type 1 treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access primary hyperoxaluria type 1 specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related primary hyperoxaluria type 1 treatment provided free
The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.
Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Check if you qualify for this primary hyperoxaluria type 1 clinical trial in New York, NY
If you're searching for primary hyperoxaluria type 1 treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced primary hyperoxaluria type 1 specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.